兆科药业

Zhaoke Pharmaceutical is a leading Chinese biopharmaceutical company that operates as the primary research, development, and manufacturing arm of Lee's Pharmaceutical Holdings Limited. Headquartered in Hefei, the company focuses on high-growth therapeutic areas including oncology, cardiovascular disease, dermatology, and women's health. Its portfolio features a mix of internally developed assets and licensed-in therapies from global partners, supported by advanced GMP-certified manufacturing facilities in Hefei and Guangzhou. A key milestone for the company is the development of Socazolimab, an anti-PD-L1 monoclonal antibody that has reached the commercial stage for cervical cancer in China. Zhaoke Pharmaceutical continues to expand its clinical pipeline with late-stage candidates like Gimatecan and Anfibatide, positioning itself as a fully integrated player in the Asian healthcare market.